Cancer Immunology - Analysis of Host and Tumor Factors for Personalized Medicine

Keywords

Microsatellite instability, Tumor microenvironment, Colorectal cancer, Medicine, KRAS

References

• Histopathological identification of colon cancer with microsatellite instability.Robert Carmichael — 2001
• Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cellsRobin J. Ely, Debra Meyerson — 2003
• Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.Hideyuki Tokuda, James W. Wendorf, Huay Yong Wang — 2003
• TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.В. П. Вавилов, В. Г. Торгунаков, Д. А. Нестерук — 2004
• Effector memory T cells, early metastasis, and survival in colorectal cancer.Franck Pagès, Anne Berger, Matthieu Camus — 2005
• Colorectal cancer epigenetics: complex simplicity.Manon van Engeland, Sarah Derks, Kim M. Smits — 2011
• A population based studyPeter McIntyre, Ruth Jepson, Stephen Leeder — 1993
• Molecular basis of colorectal cancer.Natalia B. Kouzminova, Tiffany Lu, Albert Y. Lin — 2010
• Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator.D M Graham, H D Appelman — 1990
• Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.Dan Jones, Suzanne Kamel‐Reid, David W. Bahler — 2009
• Prediction of the immunogenic potential of frameshift‐mutated antigens in microsatellite instable cancerFrank M. Speetjens, Marjolein M. Lauwen, Kees L. M. C. Franken — 2008
• CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.Yoshitaka Naito, Kazuya Saito, Kenichi Shiiba — 1998
• Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasisTakashi Chiba, Haruo Ohtani, Takayuki Mizoi — 2004
• The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profileManuela Ferracin, Roberta Gafà, Eliane Correa Miotto — 2008
• Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.Yvette Schwitalle, Matthias Kloor, Susanne Eiermann — 2008
• Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancerJohn Souglakos, Juliet Philips, R Wang — 2009
• Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictorsÅke Öberg, S. Samii, Roger Stenling — 2002
• Phenotype of Microsatellite-Stable Colorectal Carcinomas With CpG Island MethylationLucian R. Chirieac, Lanlan Shen, Paul J. Catalano — 2005
• Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancerInti Zlobec, Michal Kováč, Priska Erzberger — 2010
• Multimarker phenotype predicts adverse survival in patients with lymph node‐negative colorectal cancerInti Zlobec, Parham Minoo, Daniel Baumhoer — 2008

Cited by

• NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.W. J. Rorabaugh — 2011
• Market surveillance of in vitro diagnostics by the BfArM until end 2010: how safe are products for tumor diagnostics?R. Siekmeier, D. Wetzel — 2013
• Characterization of TCRβ sequence diversity in colorectal carcinomaLisa A. Raeburn — 2012
• The Role of KIM-1 Mediated Efferocytosis by Cancer Cells in Blocking the Immunogenicity of Tumor Cell DeathS. Nathoo — 2014
• Lymphocytes T CD4 et immunité anti-tumorale naturelle : impact de la chimiothérapie, émergence de lymphocytes T CD4 cytotoxiquesI. Peguillet — 2014
• Colon resection: is standard technique adequate?Simon J. A. Buczacki, Justin Davies — 2014
• Making every cell like HeLa a giant step for cell culture.Seema Agarwal, David L. Rimm — 2012
• Monitoring immune responses in dendritic cell based vaccination with a focus on in vivo imagingE. Aarntzen — 2013
• CD8 co-receptor modifications to enhance T cell immunotherapyIC Chua — 2013
• Chronic Traumatic Encephalopathy: The Neuropathological Legacy of Traumatic Brain InjuryJennifer Hay, Victoria E. Johnson, Douglas H. Smith — 2016
• Combat or surveillance? Evaluation of the heterogeneous inflammatory breast cancer microenvironmentJuliane M. Krüger, Cédric Wemmert, Ludovic Sternberger — 2013
• Deciphering the Adaptive Immune Response to Ovarian CancerB. Nelson — 2014
• Retrotransposon mobilization in cancer genomesTracy Ballinger, Adam D. Ewing, David Haussler — 2015
• Fusobacterium nucleatum and T-cells in Colorectal CarcinomaKosuke Mima, Yasutaka Sukawa, Reiko Nishihara — 2015
• Lymphocyte-mediated drug nanoparticle delivery to disseminated lymphoma tumors in vivoBonnie Huang — 2013
• The Role of Surgical Pathology in Guiding Cancer Immunotherapy.Scott B. Lovitch, Scott J. Rodig — 2016
• Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumoursJérôme Galon, Bernhard Mlecnik, Gabriela Bindea — 2013
• BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell InfiltrationTrevor E. Angell, Melissa G. Lechner, Julie K. Jang — 2014
• On the Bayesian Derivation of a Treatment-based Cancer OntologyMichael Gao, Jeremy L. Warner, Peter Yang — 2014
• Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating LymphocytesMatteo Bellone, Arianna Calcinotto — 2013

Related papers

• Assessing the significance of KRAS G12C mutation: Clinicopathologic features, treatments, and survival outcomes in a real-world KRAS mutant non-small cell lung cancer cohort.Wanyuan Cui, Fanny Franchini, Marliese Alexander — 2020
• Lung Cancer and KRAS -Its Molecular Biology/Genetics and Therapeutic Strategy-T. Koga, Tetsuya Mitsudomi — 2022
• Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancerLuiz H. Araujo, Bianca Marmontel de Souza, Laura Hora Rios Leite — 2020
• 127P RAS, RAF and NF1 oncogenic mutations in KRAS-mutated lung adenocarcinomaDaniele Marinelli, Simona Pisegna, Antonella Chiavassa — 2022
• Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancerLuiz H. Araujo, Bianca Mendes Souza, Laura Rabelo Leite — 2020
• KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma.David Xu, Lindsay Alpert, Peng Xu — 2016
• KRAS gene amplification to define a distinct molecular subgroup of gastroesophageal adenocarcinoma.Les Henderson, Peng Xu, Emily O’Day — 2016
• KRAS amplification and mutation are independent events in gastroesophageal adenocarcinomas (GEA).Russell W. Madison, Joseph Chao, Jeffrey S. Ross — 2019
• Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy.Sara Musetti, Leaf Huang — 2018
• Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment.Ji Li, Ming Zhao, Meng Sun — 2020